{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:24:27Z","timestamp":1760711067971,"version":"3.40.5"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Respiratory Journal"],"published-print":{"date-parts":[[2022,10,31]]},"abstract":"<jats:p>The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100\u2009mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494\u2009\u00b1\u200978 vs. score 377\u2009\u00b1\u200977, mean\u2009\u00b1\u2009SD) (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>&lt;<\/a:mo>\n                        <a:mn>0.001<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100\u2009mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.<\/jats:p>","DOI":"10.1155\/2022\/6763625","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T22:20:05Z","timestamp":1667254805000},"page":"1-5","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-2677","authenticated-orcid":true,"given":"Dongyun","family":"He","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6588-3313","authenticated-orcid":true,"given":"Zhihua","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixian","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhua","family":"Deng","sequence":"additional","affiliation":[{"name":"The Center for Translational Medicine, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7048-5427","authenticated-orcid":true,"given":"Haihong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12496"},{"issue":"2","key":"2","first-page":"77","article-title":"Parapneumonic effussion. A review of 33 cases over 6 years","volume":"18","author":"N. Sanz","year":"2005","journal-title":"Cirug\u00eda Pedi\u00e1trica: organo oficial de la Sociedad Espanola de Cirugia Pediatrica"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2935-4"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0b013e318267223a"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136994"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.13-s1-5"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03897-0"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00037004"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.05.018"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.3.760"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.8922"},{"issue":"6","key":"12","first-page":"2939","article-title":"Vascular endothelial growth factor in plasma and pleural effusion is a biomarker for outcome after bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion","volume":"36","author":"M. Tamiya","year":"2016","journal-title":"Anticancer Research"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-013-0315-7"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.18.2.221"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0109"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(05)80262-x"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940415)73:8<2087::aid-cncr2820730813>3.0.co;2-x"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2349"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.05.018"},{"issue":"3","key":"20","first-page":"1313","article-title":"Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin","volume":"36","author":"L. Jiang","year":"2016","journal-title":"Anticancer Research"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.01.094"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13238"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1002\/dc.21546"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17426"},{"issue":"9","key":"25","article-title":"Matrine promotes the efficacy and safety of platinum-based doublet chemotherapy for advanced non-small cell lung cancer","volume":"8","author":"B. Rong","year":"2015","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2019.02.07"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22966"}],"container-title":["Canadian Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2022\/6763625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2022\/6763625.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2022\/6763625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T22:20:12Z","timestamp":1667254812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/crj\/2022\/6763625\/"}},"subtitle":[],"editor":[{"given":"Anita","family":"Pye","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":27,"alternative-id":["6763625","6763625"],"URL":"https:\/\/doi.org\/10.1155\/2022\/6763625","relation":{},"ISSN":["1916-7245","1198-2241"],"issn-type":[{"type":"electronic","value":"1916-7245"},{"type":"print","value":"1198-2241"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}